SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., formerly traded on the NASDAQ Capital Market under the symbol APPX, today announced that the NASDAQ Global Market has accepted for listing the Contingent Value Rights (CVRs) related to the acquisition of APP by Fresenius Kabi, a business segment of Fresenius SE. The CVRs will trade under the symbol “APCVZ” beginning on Thursday, September 11, 2008.
